688607.SH
康众医疗
SSE · Healthcare · Medical - Devices · CN
CNY 41.26
−3.78%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 331.0M | 320.9M | 298.1M | 273.7M | 204.6M |
| Cost of Revenue | 210.0M | 203.3M | 180.3M | 167.0M | 129.7M |
| Gross Profit | 120.9M | 117.6M | 117.8M | 106.8M | 74.9M |
| Operating Expenses | |||||
| R&D Expense | 34.2M | 32.1M | 43.7M | 44.6M | 44.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 44.7M | 36.8M | 26.8M | 29.4M | 30.7M |
| Selling & Marketing Expense | 32.5M | 31.5M | 31.4M | 25.6M | 22.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 127.6M | 109.2M | 102.6M | 96.9M | 87.4M |
| Cost and Expenses | 337.6M | 312.5M | 282.9M | 263.9M | 217.1M |
| Operating Income (EBIT) | (24.0M) | (9.4M) | 17.6M | 13.8M | (10.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (24.3M) | (9.5M) | 17.7M | 15.3M | (8.9M) |
| Income Tax Expense | (3.3M) | (2.2M) | 9.7K | (105.8K) | (3.2M) |
| Bottom Line | |||||
| Net Income | (19.6M) | (6.7M) | 17.7M | 15.4M | (5.6M) |
| Earnings from Cont. Ops | (21.0M) | (7.3M) | 17.7M | 15.4M | (5.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.6M) | (6.7M) | 17.7M | 15.4M | (5.6M) |
| Per Share | |||||
| Basic EPS | (CN¥0.23) | (CN¥0.08) | CN¥0.20 | CN¥0.17 | (CN¥0.06) |
| Diluted EPS | (CN¥0.23) | (CN¥0.08) | CN¥0.20 | CN¥0.17 | (CN¥0.06) |
| Revenue Per Share | CN¥3.88 | CN¥3.85 | CN¥3.38 | CN¥3.02 | CN¥2.18 |
| Shares | |||||
| Basic Shares Outstanding | 85.3M | 83.3M | 88.3M | 90.7M | 93.8M |
| Diluted Shares Outstanding | 85.3M | 83.3M | 88.3M | 90.7M | 93.8M |
| Profitability Metrics | |||||
| EBITDA | — | (1.6M) | 23.4M | 22.4M | (5.7M) |
| D&A | — | 7.8M | 5.8M | 8.6M | 4.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026